Angiotensin Receptor Blockers: Rational Prescription Tailored to the Cardiovascular Risk and Comorbidities

Russian Journal of Cardiology - Russian Federation
doi 10.15829/1560-4071-2018-11-89-95
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Silicea - Poligraf, LLC

Related search

Angiotensin Receptor Blockers Don't Seem to Increase Risk of MI

BMJ
2005English

Angiotensin Receptor Blockers (ARBs)

CMAJ
Medicine
2011English

Review: Angiotensin II Receptor Blockers and Cardiovascular Outcomes: What Does the Future Hold?

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System
Internal MedicineEndocrinology
2003English

Angiotensin Receptor Blockers With Pleiotropic Properties: A New Standard in Cardiovascular Risk Management and Treatment of Hypertension

Rational Pharmacotherapy in Cardiology
Cardiovascular MedicinePharmacologyCardiology
2017English

Angiotensin Receptor Blockers Use and the Risk of Lung Cancer: A Meta-Analysis

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System
Internal MedicineEndocrinology
2015English

Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin Receptor Blockers

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System
Internal MedicineEndocrinology
2006English

A Study on Utilization of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients With Cardiovascular Diseases

Asian Journal of Pharmaceutical and Clinical Research
PharmacologyPharmaceutical Science
2018English

Combining Angiotensin-Receptor Blockers With Angiotensin-Converting-Enzyme Inhibitors

CMAJ
Medicine
2011English

The Potential Economic Impact of Restricted Access to Angiotensin-Receptor Blockers

CMAJ
Medicine
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy